Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocriplasmin for Focal VMA in Exudative AMD
NCT00913744Phase 2Completed
- Sponsor
- Oxurion
- Start
- Jan 2010
- Primary completion
- Dec 2012
- Modality
- Therapeutic Enzymes
- Countries
- 6
01
Overview
A Phase 2 trial of ocriplasmin in vitreomacular adhesion (VMA), sponsored by Oxurion. Started Jan 2010; status: completed.
02
Drugs
ocriplasmin
03
Conditions
vitreomacular adhesion (VMA)
Beyond the preview
Go deeper on NCT00913744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00913744.